You are here

  • Home
  • Archive
  • Volume 72, Issue 5
  • Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial

Citation Tools

Article menu
Download PDFPDF
Clinical and epidemiological research
Concise report
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Westhovens R, Keyser FD, Rekalov D, et al
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial
Annals of the Rheumatic Diseases 2013;72:741-744.